Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Celgene : to Announce Third Quarter 2017 Results on October 26, 2017; Will Host an Investor Webcast Event from the MSParis2017-7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
10/02/2017 | 01:35pm CET

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, October 26, 2017 at 9 a.m. ET to discuss third quarter 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com.

Celgene will alsohost a webcast of an investor event at the MSParis2017-7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting on Saturday, October 28 at 6:00 p.m. CEST (12:00 p.m. ET). Members of Celgene's management team and clinical investigators will discuss the data presentations at the ECTRIMS Meeting. The event will be webcast live and will be available in the Investor Relations section of the Company's web site at www.celgene.com.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'plans,' 'will,' 'outlook' and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.

View source version on businesswire.com : http://www.businesswire.com/news/home/20171002005698/en/

Celgene Corporation
Patrick E. Flanigan III, 908-673-9969
Corporate VP, Investor Relations
orBrian Gill, 908-673-9530
VP, Corporate Communications

Source: Celgene Corporation

News Provided by Acquire Media

Celgene Corporation published this content on 02 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 02 October 2017 11:34:06 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
03/15CELGENE : Announces Expiration of Cash Tender Offer for Shares of Juno Therapeut..
03/15CELGENE : Vividion Therapeutics Announces Strategic Research Collaboration with ..
03/15CELGENE : Synthetic lethality company Ideaya raises $94M
03/15ONCOMED PHARMACEUTICALS : Announces Fourth Quarter and Full Year 2017 Financial ..
03/13MANAGEMENT TRACKS : WuXi NextCode, Assembly
03/10CELGENE : Kapeller leaves Nimbus, ending CSO stint defined by virtual drug disco..
03/09CELGENE : Vividion Therapeutics Announces Strategic Research Collaboration with ..
03/09CELGENE : Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Mol..
03/09CELGENE : Set Sail With Celgene Corporation (CELG), EQT Corporation (EQT)
03/09JUNO THERAPEUTICS : Celgene completes acquisition of Juno Therapeutics
More news
News from SeekingAlpha
12:08pUnum Therapeutics Updates Proposed IPO Terms 
12:01pBiotechs Approaching New Waters 
07:52aArena Jumps On Positive Clinical Trial Results 
03/19Dosing underway in early-stage study of Agios Pharma's AG-270 
03/16Celgene's (CELG) Management Presents at Barclays Global Healthcare Conference.. 
Financials ($)
Sales 2018 14 806 M
EBIT 2018 8 491 M
Net income 2018 5 264 M
Debt 2018 274 M
Yield 2018 -
P/E ratio 2018 13,16
P/E ratio 2019 10,97
EV / Sales 2018 4,57x
EV / Sales 2019 3,68x
Capitalization 67 402 M
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 119 $
Spread / Average Target 32%
EPS Revisions
Mark J. Alles Chairman & Chief Executive Officer
Scott Andrew Smith President & Chief Operating Officer
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-4.32%358 615
PFIZER1.55%218 946
NOVARTIS-6.12%214 541
ROCHE HOLDING LTD.-11.01%199 453
MERCK AND COMPANY-2.91%150 097